Test Price
2,800 AED✅ Home Collection Available
FLI1 Gene Platelet Dense Granule Secretion Defect & Excessive Bleeding Genetic Test – DNA Labs UAE
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% analytical sensitivity verified under ISO 9001:2015 accreditation.
- Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: A mandatory pre-test genetic counselling session with pedigree chart construction, followed by a post-result physician tele-consultation.
- Insurance Support: Direct coverage verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced next-generation sequencing (NGS) test examines the entire coding region of the FLI1 gene to identify pathogenic variants responsible for platelet dense granule secretion defect, a hereditary bleeding disorder. The test requires a mandatory pre-test genetic counselling session during which a detailed pedigree chart is constructed. All processing follows stringent quality standards, delivering results within 3–4 weeks with 99.9% diagnostic sensitivity.
| Feature | Our Test: FLI1 NGS | Closest Alternative: Sanger Sequencing |
|---|---|---|
| Methodology | NGS (Next-Generation Sequencing) – full FLI1 gene analysis, CNV detection | Sanger sequencing – only point mutations in targeted exons |
| Analytical Sensitivity | >99.9% (ISO‑verified) | ~95% for sequenced regions |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Coverage | Entire FLI1 gene, including deep intronic regions and copy number variations | Selected exons only |
Physician Insight & Safety Protocols
“A molecular diagnosis for a suspected inherited platelet disorder can bring clarity and direction to your care. The FLI1 NGS analysis provides a comprehensive view of the gene, but results must always be correlated with clinical presentation and family history. I strongly recommend reviewing all findings with your treating haematologist to determine the most appropriate management strategy.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue, alter, or adjust any prescribed medication—especially anticoagulants or antiplatelet therapy—without explicit guidance from your managing physician. Abrupt changes can lead to serious bleeding or thrombotic complications.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Pregnancy, acute febrile illness, inability to provide informed consent, or an uncooperative patient for phlebotomy.
- ER Red Flags: Uncontrolled haemorrhage, signs of intracranial bleeding (severe headache, altered consciousness, sudden focal deficit), or large unexplained bruises—seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. What is the FLI1 gene test and who should consider it?
The FLI1 NGS test detects inherited mutations causing platelet dense granule secretion defect, a hereditary bleeding disorder. It is recommended for individuals with unexplained excessive bruising, prolonged bleeding after surgery or dental procedures, or a family history of bleeding disorders.
2. How is the FLI1 gene test performed and what sample is needed?
A small peripheral blood sample (3–5 mL in EDTA) is collected. For patients who prefer home collection, our VIP mobile phlebotomy service is available daily from 8 AM to 11 PM. Alternatively, a dried blood spot on an FTA card or previously extracted DNA may be accepted. The NGS platform sequences the entire FLI1 gene in our ISO 9001:2015 accredited laboratory.
3. What does a positive FLI1 mutation result mean for my bleeding risk?
A positive result confirms a genetic cause for the platelet dense granule defect. However, bleeding severity varies widely due to modifier genes and environmental factors. Clinical correlation with a consultant haematologist is essential for personalised bleeding risk assessment and management planning.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data are encrypted, access-controlled, and processed solely for diagnostic purposes. Clinical safety and patient consent are governed under Federal Decree-Law No. 4 of 2016 on Medical Liability. Your privacy and safety are our highest priority.
Clinical & Logistical Metadata
| Test Name | FLI1 Gene – Platelet Dense Granule Secretion Defect & Excessive Bleeding Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA), dried blood spot on FTA card, or extracted genomic DNA |
| Methodology Used | Next-Generation Sequencing (NGS) – full gene coverage including CNV detection |
| ICD-10-CM Code | D69.1 (Qualitative platelet defects) |
| LOINC Code | 94473-4 (FLI1 gene mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians